The pill is easier to take and the injection produces the bigger average result. An honest comparison says both sentences out loud, because most pages you will find on this question are written to sell one of the two. Orforglipron is Lilly's once-daily oral GLP-1, sold under the brand name Foundayo and tirzepatide is the weekly injection sold as Zepbound and Mounjaro. In their respective phase 3 trials the highest orforglipron dose produced an average body-weight reduction of 11.2 percent at 72 weeks while the highest tirzepatide dose produced an average reduction of about 21 percent. The pill is a real medicine with real results. The injection is simply the stronger result on average and the choice between them depends on your body, your goals and your life rather than on a leaderboard.
- Orforglipron (Foundayo) is a once-daily pill with no food or water restrictions and it produced an average weight reduction of 11.2 percent at 72 weeks in the ATTAIN-1 trial.
- Tirzepatide (Zepbound, Mounjaro) is a weekly injection that produced an average reduction of up to about 21 percent over 72 weeks in SURMOUNT-1.
- The pill suits adults who will not inject or who travel and the injection suits adults whose goals are larger or clinical.
- Both are billed by your pharmacy at its own price and neither price is set by us or marked up by us.
- The membership fee is a flat $299 a month regardless of which molecule you and your clinician choose.
We write this comparison the way we write everything here, which is to give you the numbers and the trade-offs and let your clinician and your priorities decide. A platform that earns a margin on one product has a reason to shade the comparison. We earn nothing on either molecule, so there is no shading to do.
The direct answer
If you are asking which drug produces more weight loss on average, it is tirzepatide and the margin is substantial. If you are asking which one you are more likely to take consistently for years, the honest answer is the one that fits your life and for a meaningful share of adults that is a pill. Adherence is not a footnote in obesity medicine. It is the variable that decides whether any of this works and a medicine someone quietly stops filling is a result of zero percent no matter what its trial said.
What each medicine actually is
Orforglipron is a small-molecule GLP-1 receptor agonist taken as a tablet once a day. It is the first oral GLP-1 that carries no food and water restrictions, which separates it from the older oral semaglutide tablets that required an empty stomach and careful timing. You can take Foundayo in the morning with your coffee and get on with the day.
Tirzepatide is a dual GLP-1 and GIP receptor agonist injected once weekly with a pen. It is sold under two brand names with two labels, Zepbound for weight management and Mounjaro for type 2 diabetes. The molecule is the same and the label decides what it is prescribed for and often what it costs. We cover that distinction in detail in Branded GLP-1 pass-through prices, explained.
What the trials showed
The trial results side by side
average body-weight change at 72 weeks
| Trial | Drug and dose | Average weight change | Notes |
|---|---|---|---|
| ATTAIN-1 | Orforglipron 36 mg daily | -11.2% | 54.6% of participants lost 10% or more |
| ATTAIN-1 | Orforglipron 12 mg daily | -8.4% | Dose-dependent effect |
| ATTAIN-1 | Placebo | -2.1% | Diet and activity alone |
| SURMOUNT-1 | Tirzepatide 15 mg weekly | about -21% | The strongest published average in the class |
| SURMOUNT-1 | Placebo | about -3% | Diet and activity alone |
Three readings of that table are worth making explicit. First, orforglipron's result is clinically meaningful: more than half of the participants on the highest dose lost at least 10 percent of their body weight, which is the threshold where blood pressure, blood sugar and inflammation begin moving in your favor. Second, the trials are not head to head, so the comparison between their averages is directional rather than definitive, though the gap is large enough that no honest clinician calls it a tie. Third, both trials tested the drugs alongside diet and activity and neither one replaces those. Anyone who tells you otherwise is selling something.
The full ATTAIN-1 results were published in The New England Journal of Medicine in September 2025 and the SURMOUNT-1 results were published in the same journal in 2022. We cite them so you can read the primary sources yourself, because a comparison this consequential should never rest on a summary.
Who each one genuinely suits
The pill fits a specific and large group of people. You do not want an injection, full stop. You travel for work and cannot keep pens refrigerated and timed across time zones. You have a needle aversion strong enough that a weekly pen would become a monthly pen and then a quarterly pen and then nothing. For that group orforglipron is not the compromise choice. It is the correct choice, because the best protocol is the one that actually happens.
The injection fits a different group. You are starting from a higher weight and your goals are large. You have type 2 diabetes, obstructive sleep apnea or established cardiovascular risk and your clinician wants the agent with the deepest evidence in those populations. Mounjaro carries the diabetes label and Zepbound the weight management label and which one applies is a clinical decision first and a pricing question second.
There is a third group worth naming: adults already stable on tirzepatide who are curious whether a pill would simplify their lives. The right process here is a conversation with your clinician anchored to your quarterly Biomarker Audit, not a switch made because an ad made the pill sound frictionless. Every switch restarts a titration and titrations have side effects.
The cost conversation, done honestly
Both medications are billed to you directly by your pharmacy at the pharmacy's own price and we add nothing to either one. Lilly publishes self-pay pricing through its own channels and those numbers vary by dose and move over time, so the only figure worth acting on is the one you read at the source for your specific dose on the day you decide. We deliberately do not reprint those numbers here, because a price we cannot honor is a price we have no business printing. Our guide to what branded GLP-1 medications actually cost explains the four channels that set your number and how to check each one.
What we can state with confidence is our own side of the ledger. The membership is $299 a month, flat, with a two-month commitment of $598 to start and month to month after that. The fee is identical whether your protocol is a pill or a pen, at the lowest dose or the highest, because the clinical work is the work of you, not the work of a molecule. One flat fee for the doctor. Zero markup on the medicine.
Adults asking pill versus injection are usually asking a quieter question: will anyone tell me the truth about trade-offs? The truthful structure is that adherence decides outcomes, injections currently hold the strongest average results, pills remove a barrier the injections will always have and neither choice is permanent.
The compounded option, addressed once
No comparison of oral options is complete without the cheaper pill that will be offered to you somewhere else, which is a compounded copy of semaglutide or tirzepatide in capsule form. We will not prescribe it under any circumstance. Compounded products carry no FDA-reviewed manufacturing and no verified dosing and the FDA has warned about compounded GLP-1 products repeatedly. A lower price on an unverified copy of a molecule is not a discount on this decision. It is a different decision, made in a different market, with different protections.
What switching looks like
Because the choice is not permanent, the practical question is how a switch is managed. Under our clinical protocols a change of agent follows the same discipline as any other protocol change: your current results are baselined at the quarterly audit, the new agent is titrated from its starting dose rather than resumed at an assumed equivalent and side effects are managed during the transition instead of endured through it. The Biomarker Audit after the switch shows whether the change served you. If your weight, HbA1c and other markers hold or improve, the switch was right. If they do not, the answer is a conversation rather than a shrug.
That cadence is the quiet advantage of a membership built around measurement. A platform that sells you a product has no appointment on its calendar to check whether the product worked. Our calendar has your name on it every 90 days and the labs are included in the fee rather than sold as an upsell.
How to decide, in practice
Bring three questions to any consultation on this topic, including one with us. What does the evidence say about my specific goals rather than the average patient? What will I realistically take consistently for the next two years? And what does each option cost me per month at the dose I will actually be on at month six, not month one? A clinician who answers all three plainly is a clinician worth keeping.
If you want the wider context around this decision, start with the definitive guide to Cardiometabolic Optimization, which explains why weight is treated as one part of a whole system here. For the oral options in detail, our guide to Foundayo and Wegovy Tablets goes deeper and the dose-escalation trap explains the pricing pattern to watch for on any platform that earns money per dose.
FAQ
Is orforglipron as effective as tirzepatide for weight loss?
No. In the phase 3 ATTAIN-1 trial the highest orforglipron dose produced an average body-weight reduction of 11.2 percent at 72 weeks. In SURMOUNT-1 the highest tirzepatide dose produced an average reduction of about 21 percent over the same period. Orforglipron is clinically meaningful and tirzepatide is the stronger result on average.
What is orforglipron?
Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly and sold under the brand name Foundayo. Unlike older oral semaglutide it is a small molecule with no food or water restrictions, so you can take it any time of day with or without a meal.
Who should choose the pill over the injection?
Adults who will not inject, travelers who cannot reliably refrigerate pens and patients whose clinical picture does not require the strongest available result. A medicine you will actually take consistently beats a stronger one you will avoid.
Who should choose tirzepatide over the pill?
Adults whose goals are significant: a high starting weight, type 2 diabetes, obstructive sleep apnea or established cardiovascular risk. The evidence base for tirzepatide is larger and its average result is larger and no pill preference should stand in front of a clinical need for that result.
How much does orforglipron cost compared with tirzepatide?
Both are billed by your pharmacy at its own price and Lilly publishes self-pay pricing for each through its own channels. Those prices move and vary by dose so check them at the source before you decide. The GoodLife Health membership is a flat $299 a month either way and never changes with the molecule or the dose.
Is a compounded orforglipron pill a cheaper option?
No and we would not recommend one. Compounded copies carry no FDA-reviewed manufacturing or verified dosing and the FDA has warned about compounded GLP-1 products repeatedly. GoodLife Health prescribes branded FDA-approved medications only.
Can I switch from one to the other later?
Often yes. The choice is not permanent and a clinician can move you between agents based on your results, your side effects and your quarterly labs. The right starting question is which one fits your body and your goals now rather than which one wins a headline.
Related Reading
- Branded GLP-1 pass-through prices, explained
- Oral GLP-1s: Foundayo and Wegovy Tablets explained
- The GLP-1 dose-escalation trap
- Tirzepatide maintenance dose after goal weight
- Medical Weight Loss at GoodLife Health
References
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1, NEJM). 2025. pubmed.ncbi.nlm.nih.gov/40960239/
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Compounded Drugs: FDA warnings about compounded GLP-1 products (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-compounded-semaglutide